Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up
11:40am, Monday, 25'th Nov 2024
Halozyme withdraws its proposal to acquire Evotec for 11 euro per share in cash. The company maintains its 2024 revenue guidance.
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's Why
01:05pm, Friday, 22'nd Nov 2024
Halozyme Therapeutics (HALO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
10:45am, Friday, 22'nd Nov 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Halozyme withdraws $2.1 bln buyout offer for Evotec
08:55am, Friday, 22'nd Nov 2024
Halozyme Therapeutics said on Friday it had withdrawn its proposal to acquire Evotec SE for 2 billion euros ($2.09 billion) after the German drug developer was unwilling to engage in discussions.
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions
08:35am, Friday, 22'nd Nov 2024
SAN DIEGO , Nov. 22, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDA
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
10:45am, Thursday, 21'st Nov 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
01:46pm, Tuesday, 19'th Nov 2024
Halozyme Therapeutics (HALO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
HALO vs. FOLD: Which Stock Should Value Investors Buy Now?
12:40pm, Tuesday, 19'th Nov 2024
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two companies is the
Is Halozyme Therapeutics (HALO) a Great Value Stock Right Now?
10:45am, Tuesday, 19'th Nov 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Halozyme CEO: Evotec Is Poised for Growth
04:00pm, Monday, 18'th Nov 2024
Halozyme CEO Helen Torley joins to discuss the company's intended acquisition of biotech company Evotech. She speaks with Caroline Hyde on "Bloomberg Technology.
Halozyme says €2 billion takeover of Evotech would create leader in drug discovery
07:49am, Monday, 18'th Nov 2024
Halozyme says the combined company would have an estimated $2 billion in revenue in 2025.
Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec
07:00am, Monday, 18'th Nov 2024
Would establish an innovative pharma services company with capabilities spanning drug discovery and development, biologic manufacturing and drug delivery technologies Would meaningfully diversify, sca
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
12:56pm, Friday, 15'th Nov 2024
On Thursday, Halozyme Therapeutics, Inc. HALO submitted a non-binding proposal to Evotec SE EVO to acquire the German company for 11.00 euros per share in cash, implying a fully diluted equity value
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
10:51am, Friday, 15'th Nov 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction
04:15pm, Thursday, 14'th Nov 2024
Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team SAN DIEGO , Nov. 14, 2024 /PRNewswire/
